Bertram Pitt

TL;DR: In patients with CHF, high baseline serum levels of markers of cardiac fibrosis synthesis are significantly associated with poor outcome and decrease during spironolactone therapy, and limitation of the excessive extracellular matrix turnover may be one of the various extrarenal mechanisms contributing to the beneficial effect of spironOLactone.

TL;DR: In patients with CKD and type 2 diabetes, treatment with finerenone resulted in lower risks of CKD progression and cardiovascular events than placebo, and the frequency of adverse events was similar in the two groups.

TL;DR: This post hoc analysis demonstrated greater potassium and creatinine changes and possible clinical benefits with spironolactone in patients with heart failure and preserved ejection fraction from the Americas.

TL;DR: The combination of eplerenone and enalapril was more effective in reducing LV mass and systolic blood pressure than eplererenone alone and the combination was as effective as en alapril in LVH regression and blood pressure control.

TL;DR: Enalapril treatment significantly reduced myocardial infarction, unstable angina, and cardiac mortality in patients with low ejection fractions.